Skip to content

Study · Randomized controlled trial · n = 50 · 2020

8 results

Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.

Bizino MB, Jazet IM, de Heer P, van Eyk HJ, Dekkers IA, Rensen PCN, Paiman EHM, Lamb HJ, Smit JW

Diabetologia5 Nov 2019Cited by 103 (Europe PMC)

PMID31690988 (opens in a new tab)PMCIDPMC6890592 (opens in a new tab)DOI10.1007/s00125-019-05021-6 (opens in a new tab)PepBankPUB-31690988
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

Aims/hypothesisThe aim of this work was to assess the effect of liraglutide on ectopic fat accumulation in individuals with type 2 diabetes mellitus.MethodsThis study is a pre-specified subanalysis of the MAGNetic resonance Assessment of VICTOza efficacy in the Regression of cardiovascular dysfunction In type 2 diAbetes mellitus (MAGNA VICTORIA) study, with primary endpoints being the effects of liraglutide on left ventricular diastolic and systolic function. The MAGNA VICTORIA study was a single-centre, parallel-group trial in 50 individuals with type 2 diabetes mellitus (BMI >25 kg/m2) who were randomly assigned (1:1, stratified for sex and insulin use) to receive liraglutide 1.8 mg once daily or placebo for 26 weeks, added to standard care. Participants, study personnel and outcome assessors were blinded to treatment allocation. The secondary endpoints of visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (SAT) and epicardial fat were measured with MRI. Hepatic triacylglycerol content (HTGC) and myocardial triacylglycerol content (MTGC) were quantified with proton MR spectroscopy. Between-group differences (change from baseline) were tested for significance using ANCOVA. Mean differences with 95% CIs were reported.ResultsThe trial was completed in 2016. Twenty-four participants were randomised to receive liraglutide and 26 to receive placebo. One patient in the liraglutide group withdrew consent before having received the study drug and was not included in the intention-to-treat analysis. Liraglutide (n = 23) vs placebo (n = 26) significantly reduced body weight (liraglutide 98.4 ± 13.8 kg to 94.3 ± 14.9 kg; placebo 94.5 ± 13.1 kg to 93.9 ± 13.2 kg; estimated treatment effect -4.5 [95% CI -6.4, -2.6] kg). HbA1c declined in both groups without a significant treatment effect of liraglutide vs placebo (liraglutide 66.7 ± 11.5 mmol/mol to 55.0 ± 13.2 mmol/mol [8.4 ± 1.1% to 7.3 ± 1.2%]; placebo 64.7 ± 10.2 mmol/mol to 56.9 ± 6.9 mmol/mol [8.2 ± 1.0% to 7.5 ± 0.7%]; estimated treatment effect -2.9 [95% CI -8.1, 2.3] mmol/mol or -0.3 [95% CI -0.8, 0.2]%). VAT did not change significantly between groups (liraglutide 207 ± 87 cm2 to 203 ± 88 cm2; placebo 204 ± 63 cm2 to 200 ± 55 cm2; estimated treatment effect -7 [95% CI -24, 10] cm2), while SAT was reduced by a significantly greater extent with liraglutide than with placebo (liraglutide 361 ± 142 cm2 to 339 ± 131 cm2; placebo 329 ± 107 cm2 to 333 ± 125 cm2; estimated treatment effect -29 [95% CI -51, -8] cm2). Epicardial fat did not change significantly between groups (liraglutide 8.9 ± 4.3 cm2 to 9.1 ± 4.7 cm2; placebo 9.6 ± 4.1 cm2 to 9.6 ± 4.6 cm2; estimated treatment effect 0.2 [95% CI -1.5, 1.8] cm2). Change in HTGC was not different between groups (liraglutide 18.1 ± 11.2% to 12.0 ± 7.7%; placebo 18.4 ± 9.4% to 14.7 ± 10.0%; estimated treatment effect -2.1 [95% CI -5.3, 1.0]%). MTGC was not different after treatment with liraglutide (1.5 ± 0.6% to 1.2 ± 0.6%) vs placebo (1.3 ± 0.5% to 1.2 ± 0.6%), with an estimated treatment effect of -0.1 (95% CI -0.4, 0.2)%. There were no adjudicated serious adverse events.Conclusions/interpretationCompared with placebo, liraglutide-treated participants lost significantly more body weight. Liraglutide primarily reduced subcutaneous fat but not visceral, hepatic, myocardial or epicardial fat. Future larger studies are needed to confirm the results of this secondary endpoint study.Trial registrationClinicalTrials.gov NCT01761318.FundingThis study was funded by Novo Nordisk A/S (Bagsvaerd, Denmark).
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, visceral adipose tissue did not change significantly between liraglutide and placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not change visceral fat differently from placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeVisceral adipose tissue (VAT)
    Study

    n = 49

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    1.8 mg once daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    VAT did not change significantly between groups (liraglutide 207 ± 87 cm2 to 203 ± 88 cm2; placebo 204 ± 63 cm2 to 200 ± 55 cm2; estimated treatment effect -7 [95% CI -24, 10] cm2)
    2 context sentences
    Summary · context
    The secondary endpoints of visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (SAT) and epicardial fat were measured with MRI.
    Summary · context
    The MAGNA VICTORIA study was a single-centre, parallel-group trial in 50 individuals with type 2 diabetes mellitus (BMI >25 kg/m2) who were randomly assigned (1:1, stratified for sex and insulin use) to receive liraglutide 1.8 mg once daily or placebo for 26 weeks, added to standard care.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide reduced abdominal subcutaneous adipose tissue significantly more than placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide reduced fat under the skin of the abdomen more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseAbdominal subcutaneous adipose tissue (SAT)
    Study

    n = 49

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    1.8 mg once daily · 26 weeksAs given in this study (human).

    Measurements

    Estimated treatment effect on SAT
    −29 cm<sup>2</sup>
    liraglutide vs placebo

    Source sentences

    Summary
    SAT was reduced by a significantly greater extent with liraglutide than with placebo (liraglutide 361 ± 142 cm2 to 339 ± 131 cm2; placebo 329 ± 107 cm2 to 333 ± 125 cm2; estimated treatment effect -29 [95% CI -51, -8] cm2)
    2 context sentences
    Summary · context
    The secondary endpoints of visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (SAT) and epicardial fat were measured with MRI.
    Summary · context
    The MAGNA VICTORIA study was a single-centre, parallel-group trial in 50 individuals with type 2 diabetes mellitus (BMI >25 kg/m2) who were randomly assigned (1:1, stratified for sex and insulin use) to receive liraglutide 1.8 mg once daily or placebo for 26 weeks, added to standard care.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, epicardial fat did not change significantly between liraglutide and placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not change fat around the heart differently from placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeEpicardial fat
    Study

    n = 49

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body composition · Cardiovascular
    Studied dose
    1.8 mg once daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Epicardial fat did not change significantly between groups (liraglutide 8.9 ± 4.3 cm2 to 9.1 ± 4.7 cm2; placebo 9.6 ± 4.1 cm2 to 9.6 ± 4.6 cm2; estimated treatment effect 0.2 [95% CI -1.5, 1.8] cm2).
    2 context sentences
    Summary · context
    The secondary endpoints of visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (SAT) and epicardial fat were measured with MRI.
    Summary · context
    The MAGNA VICTORIA study was a single-centre, parallel-group trial in 50 individuals with type 2 diabetes mellitus (BMI >25 kg/m2) who were randomly assigned (1:1, stratified for sex and insulin use) to receive liraglutide 1.8 mg once daily or placebo for 26 weeks, added to standard care.
  4. 04HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, no adjudicated serious adverse events occurred in the trial.

    In plain wordsIn adults with type 2 diabetes, the trial recorded no serious adverse events that an expert panel confirmed.

    Peptide
    Liraglutide
    Outcome
    No significant changeAdjudicated serious adverse events
    Study

    n = 50

    Outcome group
    Adverse events · Whole body
    Studied dose
    1.8 mg once daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no adjudicated serious adverse events.
    1 context sentence
    Summary · context
    The MAGNA VICTORIA study was a single-centre, parallel-group trial in 50 individuals with type 2 diabetes mellitus (BMI >25 kg/m2) who were randomly assigned (1:1, stratified for sex and insulin use) to receive liraglutide 1.8 mg once daily or placebo for 26 weeks, added to standard care.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide 1.8 mg reduced body weight more than placebo over 26 weeks.

    In plain wordsIn adults with type 2 diabetes, liraglutide reduced body weight more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 49

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg once daily · 26 weeksAs given in this study (human).

    Measurements

    Estimated treatment effect on body weight
    −4.5 kg
    liraglutide vs placebo

    Source sentences

    Summary
    Liraglutide (n = 23) vs placebo (n = 26) significantly reduced body weight (liraglutide 98.4 ± 13.8 kg to 94.3 ± 14.9 kg; placebo 94.5 ± 13.1 kg to 93.9 ± 13.2 kg; estimated treatment effect -4.5 [95% CI -6.4, -2.6] kg).
    1 context sentence
    Summary · context
    The MAGNA VICTORIA study was a single-centre, parallel-group trial in 50 individuals with type 2 diabetes mellitus (BMI >25 kg/m2) who were randomly assigned (1:1, stratified for sex and insulin use) to receive liraglutide 1.8 mg once daily or placebo for 26 weeks, added to standard care.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, HbA1c declined in both groups, with no significant treatment effect of liraglutide versus placebo.

    In plain wordsIn adults with type 2 diabetes, HbA1c fell in both groups, and liraglutide did not lower it more than placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c change
    Study

    n = 49

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg once daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    HbA1c declined in both groups without a significant treatment effect of liraglutide vs placebo
    1 context sentence
    Summary · context
    The MAGNA VICTORIA study was a single-centre, parallel-group trial in 50 individuals with type 2 diabetes mellitus (BMI >25 kg/m2) who were randomly assigned (1:1, stratified for sex and insulin use) to receive liraglutide 1.8 mg once daily or placebo for 26 weeks, added to standard care.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the change in hepatic triacylglycerol content did not differ between liraglutide and placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not change liver fat differently from placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeHepatic triacylglycerol content (HTGC)
    Study

    n = 49

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1.8 mg once daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Change in HTGC was not different between groups (liraglutide 18.1 ± 11.2% to 12.0 ± 7.7%; placebo 18.4 ± 9.4% to 14.7 ± 10.0%; estimated treatment effect -2.1 [95% CI -5.3, 1.0]%).
    2 context sentences
    Summary · context
    Hepatic triacylglycerol content (HTGC) and myocardial triacylglycerol content (MTGC) were quantified with proton MR spectroscopy.
    Summary · context
    The MAGNA VICTORIA study was a single-centre, parallel-group trial in 50 individuals with type 2 diabetes mellitus (BMI >25 kg/m2) who were randomly assigned (1:1, stratified for sex and insulin use) to receive liraglutide 1.8 mg once daily or placebo for 26 weeks, added to standard care.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, myocardial triacylglycerol content did not differ after liraglutide versus placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not change fat in the heart muscle differently from placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeMyocardial triacylglycerol content (MTGC)
    Study

    n = 49

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg once daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    MTGC was not different after treatment with liraglutide (1.5 ± 0.6% to 1.2 ± 0.6%) vs placebo (1.3 ± 0.5% to 1.2 ± 0.6%), with an estimated treatment effect of -0.1 (95% CI -0.4, 0.2)%.
    2 context sentences
    Summary · context
    Hepatic triacylglycerol content (HTGC) and myocardial triacylglycerol content (MTGC) were quantified with proton MR spectroscopy.
    Summary · context
    The MAGNA VICTORIA study was a single-centre, parallel-group trial in 50 individuals with type 2 diabetes mellitus (BMI >25 kg/m2) who were randomly assigned (1:1, stratified for sex and insulin use) to receive liraglutide 1.8 mg once daily or placebo for 26 weeks, added to standard care.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01761318

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

Leiden University Medical Centern = 50Nov 2013 to Mar 2016

Diabetes Mellitus Type 2 · Metabolic Syndrome · Cardiovascular Disease · Diastolic Dysfunction · Fatty Liver

Trial pageClinicalTrials.govUpdated 5 May 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.